Market Overview

Benzinga's Top Initiations

Share:
Benzinga's Top Initiations
Related GEVA
Ultragenyx Downgraded At Morgan Stanley, Valuation 'Stretched' And Pipeline Faces Execution Risk
JMP Starts Ultragenyx At Outperform, Pipeline Maturity Expected To Continue
Related
Here's Why There's Been A Rush Of Biotech Offerings
UBS: Biotech Will Continue To Outperform In 2015

Goldman Sachs initiated coverage on shares of Synageva BioPharma (NASDAQ: GEVA) with a “buy” rating. The target price for Synageva BioPharma is set to $72. Synageva BioPharma's shares closed at $52.61 yesterday.

Bank of America initiated coverage on shares of Prothena (NASDAQ: PRTA) with a “neutral” rating. The target price for Prothena is set to $28. Prothena's shares closed at $27.09 yesterday.

Analysts at Mizuho Securities initiated coverage on shares of Abercrombie & Fitch Company (NYSE: ANF) with a “neutral” rating. Abercrombie & Fitch's shares closed at $35.16 yesterday.

Analysts at DA Davidson initiated coverage on shares of Exterran Holdings (NYSE: EXH) with a “neutral” rating. The target price for Exterran Holdings is set to $35. Exterran's shares closed at $32.78 yesterday.

Latest Ratings for GEVA

DateFirmActionFromTo
May 2015BairdDowngradesOutperformNeutral
Mar 2015JP MorganDowngradesOverweightNeutral
Feb 2015CitigroupMaintainsNeutral

View More Analyst Ratings for GEVA
View the Latest Analyst Ratings

Posted-In: Top InitiationsInitiation Analyst Ratings

 

Related Articles (ANF + EXH)

View Comments and Join the Discussion!

Get Benzinga's Newsletters